COMMUNIQUÉS West-GlobeNewswire

Tonix Pharmaceuticals Plans to Expand TNX-102 SL Phase 3 Program Beyond PTSD to Include Fibromyalgia
04/04/2019
Encouraging FDA Meeting Minutes Support Phase 3 Development of TNX-102 SL 5.6 mg in Fibromyalgia NEW YORK, April 04, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a [...]
RTI Surgical® Applauds Blue Cross and Blue Shield of Alabama’s Positive Coverage Decision for Minimally Invasive Sacroiliac Joint Fusion Surgery
04/04/2019
Decision may help more patients access RTI’s SImmetry ® Sacroiliac Joint Fusion System, a minimally invasive surgical solution for sacroiliac (SI) joint dysfunction Blue Cross and Blue Shield of Alabama is the largest [...]
Theratechnologies Announces Financial Results for the First Quarter of 2019
04/04/2019
MONTREAL, April 04, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced its financial results for the first quarter ended February 28, 2019. First quarter 2019 financial [...]
Theratechnologies annonce ses résultats financiers pour le premier trimestre de 2019
04/04/2019
MONTRÉAL, 04 avr. 2019 (GLOBE NEWSWIRE) -- Theratechnologies inc. (« Theratechnologies ») (TSX : TH) a annoncé aujourd’hui ses résultats financiers pour le premier trimestre clos le 28 février 2019. Faits saillants [...]
Aleafia Health Appoints Lead Independent Director
04/04/2019
TORONTO, April 04, 2019 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSX: ALEF, OTC: ALEAF, FRA: ARAH) (“ Aleafia Health ” or the “ Company ”) has appointed Loreto Grimaldi as the Lead Independent Director of the Company’s [...]
Myriad, AstraZeneca and Merck Expand Companion Diagnostic Partnership
04/04/2019
BRACAnalysis CDx® Test Will Be Used to Identify Germline BRCA Mutations in Men with Metastatic Castrate-Resistant Prostate Cancer SALT LAKE CITY, April 04, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN [...]
Managers’ transactions
04/04/2019
Company announcement No. 6/2019 For further information please contact: Martin Riise, Senior Director, Investor Relations, Tel: +45 5339 2250 Camilla Lercke, Head of Media Relations, Tel: +45 5339 2384 About Chr. Hansen [...]
Ogilvy Health Hires Industry Veteran Dan Chichester as Chief Experience Officer
04/04/2019
PARSIPPANY, N.J., April 04, 2019 (GLOBE NEWSWIRE) -- Ogilvy Health, part of The Ogilvy Group ( www.ogilvy.com ), today announced Dan Chichester has re-joined the network following a five-year hiatus, returning in the [...]
Algernon Pharmaceuticals Appoints Leading Inflammatory Bowel Disease Expert Dr. Walter Reinisch to Its Medical and Scientific Advisory Board
04/04/2019
VANCOUVER, British Columbia, April 04, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development [...]
Intercept to Present Results from the First Successful Phase 3 Trial in Patients with Liver Fibrosis Due to NASH at the International Liver Congress™ 2019
04/04/2019
Multiple additional abstracts evaluating obeticholic acid (OCA) for the treatment of patients with progressive non-viral liver diseases to be presented at the meeting NEW YORK, April 04, 2019 (GLOBE NEWSWIRE) -- [...]
Homology Medicines Announces FDA Clearance of Investigational New Drug Application for HMI-102 Gene Therapy Candidate for PKU
04/04/2019
- Phase 1/2 pheNIX Trial Would Represent First PKU Gene Therapy to Enter the Clinic - - Initial Clinical Data Expected by the End of 2019 - BEDFORD, Mass., April 04, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. ( [...]
ContraFect Announces Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
04/04/2019
Vance G. Fowler, M.D., Professor of Medicine in the Division of Infectious Diseases, Duke University to Present New Data from the Exebacase Phase 2 Study YONKERS, New York, April 04, 2019 (GLOBE NEWSWIRE) -- ContraFect [...]
RedHill Biopharma to Present at Three Conferences in April
04/04/2019
TEL-AVIV, Israel and RALEIGH, N.C., April 04, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily [...]
InspireMD, Inc. Announces Pricing of $2.4 Million Public Offering of Common Stock
04/04/2019
TEL AVIV, Israel, April 04, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery [...]
Changes to the Management Board of AS Olainfarm
04/04/2019
JSC Olainfarm hereby informs about the following decisions taken by its Supervisory Council on April 01, 2019: To recall Inga Krūkle from the position of Board member of AS Olainfarm; Appoint Lauris Macijevskis to the [...]
Announcement regarding the election of the Chairperson and deputy of the Council of JSC Olainfarm
04/04/2019
On 1 st of April, a new Supervisory Council has been elected at the Extraordinary Shareholders' meeting of JSC Olainfarm for a term of five years. Appointed members of the Supervisory Council are Gundars Bērziņš, Jānis [...]
Oxurion NV announces full enrollment of its Phase 2 trial evaluating efficacy and safety of the combination of anti-PlGF (THR-317) and anti-VEGF (ranibizumab) for treatment of DME, ahead of schedule
04/04/2019
Leuven, Belgium, April 04, 2019 (GLOBE NEWSWIRE) -- Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diabetic eye disease, announces [...]
Genfit: GENFIT Announces Upcoming Presentations on NASH, PBC and Diagnostics at the European Association for the Study of the Liver (EASL) International Liver Congress 2019
04/04/2019
GENFIT Announces Upcoming Presentations on NASH, PBC and Diagnostics at the European Association for the Study of the Liver (EASL) International Liver Congress 2019 Elafibranor Phase 2 data in PBC accepted for late- [...]
Genfit: GENFIT annonce la présentation de nouvelles données sur ses programmes NASH, PBC et Diagnostic au congrès EASL ILC 2019
04/04/2019
GENFIT annonce la présentation de nouvelles données sur ses programmes NASH, PBC et Diagnostic au congrès EASL ILC 2019 Données de Phase 2 pour elafibranor dans la PBC acceptées en « late breaker » pour une présentation [...]

Pages